NEW
-
앱클론(주) 서울특별시 구로구 디지털로 285
(구로동, 에이스트윈타워1차) 14층
T. 02-2109-1294
F. 02-2109-1296
E. abclon@abclon.com
Based on this innovative new drug development platform and experience in developing antibody therapy,
AbClon will lead the development of intractable therapy, giving hope to patients and their families.
| 번호 | 제목 | 날짜 | 조회 |
| 24 |
Biosynergy Antibody Biosynergy AntibodyBiosynergy AntibodyBiosynergy AntibodyBiosynergy AntibodyBiosynergy Antibody
|
2021-01-02 | 69 |
| 24 |
Biosynergy Antibody
|
2021-01-02 | 69 |
| 24 |
Biosynergy Antibody
|
2021-01-02 | 69 |
| 24 |
Biosynergy Antibody |
2021-01-02 | 69 |
| 24 |
Biosynergy Antibody |
2021-01-02 | 69 |
| 24 |
Biosynergy Antibody |
2021-01-02 | 69 |
| 24 |
Biosynergy Antibody |
2021-01-02 | 69 |
| 24 |
Biosynergy Antibody |
2021-01-02 | 69 |
| 24 |
Biosynergy Antibody |
2021-01-02 | 69 |